Subject(s)
Athletic Injuries/prevention & control , Infectious Mononucleosis/complications , Spleen/injuries , Splenic Rupture/prevention & control , Humans , Infectious Mononucleosis/pathology , Rupture, Spontaneous/prevention & control , Spleen/pathology , Splenic Rupture/etiology , Splenomegaly/etiologySubject(s)
Athletic Injuries/epidemiology , Brain Concussion/epidemiology , Cognition Disorders/epidemiology , Brain/physiopathology , Canada/epidemiology , Causality , Electromyography/methods , Electromyography/statistics & numerical data , Humans , Probability , Recurrence , Risk Factors , Severity of Illness Index , Time Factors , Transcranial Magnetic Stimulation/methodsSubject(s)
Anti-Bacterial Agents/therapeutic use , Cellulitis/drug therapy , Cellulitis/microbiology , Clindamycin/therapeutic use , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Ambulatory Care Facilities , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/economics , Clindamycin/administration & dosage , Clindamycin/economics , Hospitalization , Humans , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Risk Factors , Staphylococcal Skin Infections/drug therapy , Trimethoprim, Sulfamethoxazole Drug Combination/administration & dosage , Trimethoprim, Sulfamethoxazole Drug Combination/economicsSubject(s)
Anti-Bacterial Agents/therapeutic use , Bacterial Infections/drug therapy , Prostatitis/drug therapy , Acute Disease , Aminoglycosides/therapeutic use , Anti-Bacterial Agents/administration & dosage , Cephalosporins/therapeutic use , Drug Administration Schedule , Drug Therapy, Combination , Fluoroquinolones/therapeutic use , Humans , MaleSubject(s)
Adrenal Cortex Hormones/therapeutic use , Adrenergic beta-2 Receptor Antagonists/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Asthma, Exercise-Induced/prevention & control , Athletes , Bronchodilator Agents/therapeutic use , Administration, Inhalation , Adrenal Cortex Hormones/administration & dosage , Adrenergic beta-2 Receptor Antagonists/administration & dosage , Adrenergic beta-2 Receptor Antagonists/adverse effects , Albuterol/administration & dosage , Albuterol/therapeutic use , Androstadienes/administration & dosage , Androstadienes/therapeutic use , Anti-Inflammatory Agents/administration & dosage , Asthma, Exercise-Induced/drug therapy , Asthma, Exercise-Induced/physiopathology , Bronchodilator Agents/administration & dosage , Chemoprevention/methods , Clinical Trials as Topic , Fluticasone , Humans , TachyphylaxisABSTRACT
BACKGROUND: Overweight and obesity are at epidemic proportions. This study examines the attitudes and actions of Oklahoma clinicians in obesity treatment, and the characteristics and perceptions of a subset of their patients who lost weight and were able to maintain weight loss. METHODS: Our study was a small mixed method study involving both surveys and interviews. Descriptive statistics were calculated, content analysis of interviews performed, and a model outline for obesity counseling was developed. RESULTS: Only 38% of the 66 clinicians surveyed try to motivate their patients to lose weight. Patients interviewed recommended that clinicians treat obesity as a medical problem. We incorporated themes from the patient interviews into the S-MASS model for obesity screening and counseling.This was positively reviewed by clinicians and patients. CONCLUSION: The S-MASS model can function as a guide to help the clinician/patient team develop successful strategies for weight loss and maintenance of weight loss.